

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Pollak, et al

Serial No.: Continuation of 09/234,651

Filed: Herewith

For: CIRCULATING INSULIN-LIKE
GROWTH FACTOR-I AND
PROSTATE CANCER RISK

§
§
§
§
§
§
§
§
§

Group Art Unit: 1642

Examiner: A. Holleran

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 C.F.R. § 1.97, Applicant hereby makes of record the references set forth in the attached modified form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and not in any order based on their pertinence.

Pursuant to 37 C.F.R. §1.98(d), no copies of the cited references are enclosed since the references were provided in the parent application, U.S. Serial No. 09/234,651.

It is requested that the Examiner fully consider the cited references and that they be cited on the front of any patent issuing from this application.

An early action on the merits is respectfully requested.

Respectfully submitted,

Brian J. Hubbard
Brian J. Hubbard
Reg. No. 45,873

Date: Dec. 18, 2001

HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202
Phone: 214-651-5058
Fax: 214-651-5940
Docket No.: 28758.57

D-912566.1

| |
|---|
| EXPRESS MAIL NO.: EL 828065286 US |
| DATE OF DEPOSIT: <u>December 18, 2001</u> |
| This paper is being deposited with the U.S. Postal Service Express Mail Post Office to Addressee service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231. |
| <i>Sandra Kubin</i> |
| SANDRA KUBIN |

| | | | | | | | |
|---|----|--|------|------------------------------|-------|--|----------------------------------|
| In Place of Form PTO-1449 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 28758.57 | | SERIAL NO. Continuation of 09/234,651 | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANT Pollak, et al. | | | |
| | | | | FILING DATE Herewith | | GROUP 1642 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | | | | | | | YES NO |
| | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.). | | | | | | | |
| | AA | Cohen, et al., "Cell Proliferation in Carcinogenesis," Science, 249(4972): 1007(5), Abstract Only | | | | | |
| | AB | Cohen, et al., "Genetic Errors, Cell Proliferation, and Carcinogenesis," Cancer Research, 51:6493-6505 (1991) | | | | | |
| | AC | Jones, et al., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions," Endocrine Reviews, 16(1): 3-34 (1995) | | | | | |
| | AD | Juul, et al., "Serum Insulin-Like Growth Factor-I in 1030 Healthy Children, Adolescents, and Adults: Relation to Age, Sex, Stage of Puberty, Testicular Size, and Body Mass Index," J. of Clinical Endocr. and Metab., 78(3): 744-752 (1994) | | | | | |
| | AE | Juul, et al., "Serum Levels of Insulin-Like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3) in Healthy Children, and Adolescents: The Relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, Age, Sex, Body Mass Index, and Pubertal Maturation," J. of Clinical Endocr. and Metab., 80(8): 2534-2542 (1995) | | | | | |
| | AF | Pollak, et al., "Effect of Tamoxifen on Serum Insulin-Like Growth Factor I Levels in Stage I Breast Cancer Patients," Journal of the Nat. Cancer Instit., 82(21): 1693-1697 (1990) | | | | | |
| | AG | Huynh, et al., "A Role for Insulin-Like Growth Factor Binding Protein 5 in the Antiproliferative Action of the Antiestrogen ICI 182780," Cell Growth and Differentiation, 7:1501-1506 (1996) | | | | | |
| | AH | Huynh, et al., "Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells," The Journal of Biological Chemistry, 271(2): 1016-1021 (1996) | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. | | | | | | | |

| | | | |
|---|---|------------------------------|--|
| In Place of Form PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 28758.57 | SERIAL NO. Continuation of 09/234,651 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | APPLICANT Pollak, et al. | |
| | | FILING DATE Herewith | GROUP 1642 |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.). | | | |
| AI | Huynh, et al., "Regulation of Insulin-like Growth Factor I Receptor Expression by the Pure Antiestrogen ICI 182780," Clinical Cancer Research, 2:2037-2042 (1996) | | |
| AJ | Mantzoros, et al., "Insulin-like Growth Factor 1 in Relation to Prostate Cancer and Benign Prostatic Hyperplasia," B.J. of Cancer, 76(9): 1115-1118 (1997) | | |
| AK | Thissen, et al., "Nutritional Regulation of the Insulin-Like Growth Factors," Endocrine Reviews, 15(1): 80-101 (1994) | | |
| AL | Zarandi, et al., "Synthesis and Biological Activities of Highly Potent Antagonists of Growth Hormone-Releasing Hormone," Proc. Natl. Acad. Sci USA, 91:12298-12302 (1994) | | |
| AM | Pollak, et al., "Rationale for Combined Antiestrogen-Somatostatin Analogue Therapy of Breast Cancer," Adjuvant Therapy of Cancer VIII, pp. 145-152 (1997) | | |
| AN | Rechler, Editorial: Growth Inhibition by Insulin-Like Growth Factor (IGF) Binding Protein-3-What's a IGF Got To Do With It?, Endocrinology, 138(7): 2645-2647 (1997) | | |
| AO | "Prostate Cancer: Progress in Screening, Prevention Holds Promise," Harvard Health Letter, 23(9):4-5 (1998) | | |
| AP | Chan, et al., "Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study," Science, 279:563-566 (1998) | | |
| AQ | Cohen, Serum Insulin-Like Growth Factor-I Levels and Prostate Cancer Risk - Interpreting the Evidence," J. of the Nat. Cancer Instit., 90(12): 876-879 (1998) | | |
| AR | Wolk, et al., "Insulin-Like Growth Factor I and Prostate Cancer Risk: a Population-Based, Case-Control Study," J. of the Nat. Cancer Instit., 90(12): 911-915 (1998) | | |
| AS | Ho, et al., "Insulin-Like Growth Factor-Binding Protein-2 in Patients With Prostate Carcinoma and Benign Prostatic Hyperplasia," Clinical Endocrinology, 46: 333-342 (1997) | | |
| AT | Tennant, et al., "Changes in Insulin-Like Growth Factor System in Prostate Cancer," J. Investigative Medicine, 44(1): 154A (1996) Abstract Only | | |
| AU | Miglietta, et al., "Suramin and Serum Insulin-Like Growth Factor Levels in Metastatic Cancer Patients," Anticancer Research, 13:2473-2476 (1993) | | |
| AV | Ware, "Growth Factors and Their Receptors as Determinants in the Proliferation and Metastasis of Human Prostate Cancer," Cancer and Metastasis Reviews, 12:287-301 (1993) | | |
| EXAMINER | | DATE CONSIDERED | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. | | | |

| | | | | |
|--|----|--|------------------------------|--|
| In Place of Form PTO-1449 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 28758.57 | SERIAL NO. Continuation of 09/234,651 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | APPLICANT Pollak, et al. | |
| | | | FILING DATE Herewith | GROUP 1642 |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.). | | | | |
| | AW | Hsing, et al., "Regulation of Apoptosis Induced by Transforming Growth Factor-Beta 1 in Nontumorigenic Rate Prostatic Epithelial Cell Lines, Cancer Research, 56(22): 5146-5149 (1996) Abstract Only | | |
| | AX | Culig, et al., "Androgen Receptor Activation in Prostatic Tumor Cell Lines by Insulin-Like Growth Factor-I, Keratinocyte Growth Factor, and Epidermal Growth Factor," Cancer Research, 54(20): 5474-5478 (1994) Abstract Only | | |
| | AY | Cohen, et al., "The IGF Axis in the Prostate," Hormone Metab. Research, 26(2): 81-84 (1994) Abstract Only | | |
| | AZ | Iwamura, et al., "Insulin-Like Growth Factor I: Action and Receptor Characterization in Human Prostate Cancer Cell Lines," Prostate, 22(3): 243-252 (1993) Abstract Only | | |
| | BA | Cohen, et al., "Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells," J. Clinical Endocrin. Metab., 73(2): 401-407 (1991) Abstract Only | | |
| | BB | Cohen, et al., "Prostate-Specific Antigen (PSA) in an Insulin-Like Growth Factor Binding Protein-3 Protease Found in Seminal Plasma," J. Clin. Metab., 75(4): 1046-1053 (1992) Abstract Only | | |
| | BC | Huynh, et al., "A Role for Insulin-Like Growth Factor Binding Protein 5 in the Antiproliferative Action of the Antiestrogen ICI 182780," Cell Growth Differentiation, 7(11): 1501-1506 (1996) Abstract Only | | |
| | BD | "Final Report on the Aspirin Component of the Ongoing Physician's Health Study Steering Committee of the Physician's Health Study Research Group," N. Eng. J. of Medicine, 321(3): 129-135 (1989) Abstract Only | | |
| | BE | Gann, et al., "Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer," J. Natl. Cancer Institute, 88(16): 1118-1126 (1996) Abstract Only | | |
| | BF | Gann, et al., "A Prospective Evaluation of Plasma Prostate-Specific Antigen for Detection of Prostatic Cancer," JAMA, 273(4): 289-294 (1995) Abstract Only | | |
| | BG | Giovannucci, et al., "The CAG Repeat Within the Androgen Receptor Gene and Its Relationship to Prostate Cancer," Proc. Natl. Acad Sci USA, 94(15): 8272 (1997) Abstract Only | | |
| | BH | Goodman-Gruen, et al., "Epidemiology of Insulin-Like Growth Factor-I in Elderly Men and Women. The Rancho Bernardo Study," Am. J. Epidemiol., 146(4): 357 (1997) Abstract Only | | |
| EXAMINER | | DATE CONSIDERED | | |
| *EXAMINER: | | Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. | | |

| | | | | |
|--|----|--|------------------------------|--|
| In Place of Form PTO-1449 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 28758.57 | SERIAL NO. Continuation of 09/234,651 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | APPLICANT Pollak, et al. | |
| | | | FILING DATE Herewith | GROUP 1642 |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.). | | | | |
| | BI | Andersson, et al., "Body Size and Prostate Cancer: a 20-year Follow-up Study Among 135006 Swedish Construction Workers," J. Natl. Cancer Instit., 89(5): 385-389 (1997) Abstract Only | | |
| | BJ | La Vecchia, et al., "Height and Cancer Risk in a Network of Case-Control Studies From Northern Italy," Interrogatory. J. Cancer, 45(2): 275-279 (1990) Abstract Only | | |
| | BK | Hebert, et al., "Adult Height and Incidence of Cancer in Male Physicians (United States)," Cancer Causes Control, 8(4): 591-597 (1997) Abstract Only | | |
| | BL | Tibblin, et al., "High Birthweight as a Predictor of Prostate Cancer Risk," Epidemiology, 6(4): 423-424 (1995) Abstract Only | | |
| | BM | Lassarre, et al., "Serum Insulin-Like Growth Factors and Insulin-Like Growth Factor Binding Proteins in the Human Fetus. Relationships With Growth in Normal Subjects and in Subjects With Intrauterine Growth Retardation," Pediatr Res., 29(3): 219-225 (1991) Abstract Only | | |
| | BN | Boyle, et al., "Geographical and Temporal Patters of Incidence and Mortality From Prostate Cancer," Urology, 46(3, Suppl.A): 47-55 (1995) Abstract Only | | |
| | BO | Meredith, "Finding From Asia, Australia, Europe, and North America on Secular Change in Mean Height of Children, Youths, and Young Adults," Am. J. Phys. Anthropol., 44(2): 315-325 (1976) Abstract Only | | |
| | BP | Aquilina, et al., "Androgen Deprivation as a Strategy for Prostate Cancer Chemoprevention," J. Natl. Cancer Instit., 89(10): 689-696 (1997) Abstract Only | | |
| | BQ | Pollak, et al., "Somastatin Analogue SMS 201-995 Reduces Serum IGF-I Levels in Patients With Neoplasms Potentially Dependent on IGF-I," Anticancer Research, 9(4): 889-891 (1989) Abstract Only | | |
| | BR | Rudman, et al., "Effects of Human Growth Hormone in Men Over 60 Years Old," N. Engl. J. Med., 323(1): 1-6 (1990) Abstract Only | | |
| | BS | Finne, P., et al., "Insulin-like Growth Factor I is Not a Useful Marker of Prostate Cancer in Men With Elevated Levels of Prostate-Specific Antigen," J. Clinical Endocrinology & Metabolism, 85(8): 2744-2747 (2000) | | |
| | BT | Lash, T.L., "Re: Insulin-like Growth Factor I and Prostate Cancer Risk: a Population-Based, Case-Control Study," J. Natl. Cancer Inst. 90(23): 1841 | | |
| EXAMINER | | DATE CONSIDERED | | |
| *EXAMINER: | | Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. | | |